SEC Filing Summary
Entity and period: The supplied filing is Zafgen, Inc.’s Form 10-Q for the quarter ended June 30, 2018, filed August 9, 2018. It is not a Larimar Therapeutics filing; the company-name mismatch should be confirmed before relying on this summary.
Business context and reporting period
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases. Its lead candidate, ZGN-1061, was in Phase 2 development for type 2 diabetes; ZGN-1258 was in IND-enabling nonclinical work, initially targeting Prader-Willi syndrome (PWS). The company had no product revenue and reported results for the three and six months ended June 30, 2018, compared with the same 2017 periods.
Financial results and liquidity
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $12.2m | $10.5m | $24.6m | $20.2m |
| General and administrative expense | $3.4m | $3.0m | $6.6m | $6.6m |
| Net loss | $15.8m | $13.3m | $31.7m | $26.4m |
| Basic and diluted loss per share | $0.57 | $0.49 | $1.15 | $0.96 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $26.6m | $21.9m |
Gross margin is not applicable because the company reported no revenue. At June 30, 2018, cash and cash equivalents were $40.7m and marketable securities were $35.1m, totaling $75.8m. Current assets were $78.0m and current liabilities $9.3m. Total liabilities were $27.8m. Notes payable had a $20.3m carrying balance, including accrued final-payment interest; the loan’s stated principal was $20.0m. The loan carried a variable rate of prime plus 1.25% and an 8% final payment, with minimum liquidity covenants.
For the first six months, investing activities provided $26.3m, principally from marketable-security maturities and sales, while financing activities provided $0.2m. Cash and cash equivalents declined only $0.03m, but this does not represent operating cash generation: operating activities used $26.6m, offset by investment-portfolio turnover. Accumulated deficit was $321.3m.
Material changes versus prior comparable periods
- Q2 net loss increased $2.4m year over year; first-half net loss increased $5.4m.
- First-half R&D expense rose $4.4m. New ZGN-1258 spending ($4.5m) and higher discovery and unallocated costs more than offset lower ZGN-1061 nonclinical and manufacturing spending.
- Interest expense increased because of the Silicon Valley Bank term loan entered into in December 2017; the prior credit facility had been repaid in December 2017.
- Cash, cash equivalents and marketable securities fell from $102.1m at December 31, 2017 to $75.8m at June 30, 2018, before the subsequent equity financing.
Outlook, commentary, risks and unusual items
- On July 2, 2018, after quarter-end, Zafgen sold 9.2m shares at $7.50 each, raising approximately $64.6m net. The filing estimated pro forma cash, cash equivalents and marketable securities of $140.4m as of June 30 after the offering. Management expected available funds to support at least one year of operations from the filing date, subject to assumptions and development needs.
- Management planned to report results from the additional ZGN-1061 1.8 mg cohort early in 2019 and aimed to begin ZGN-1258 Phase 1 development by the end of 2018, subject to supportive progress and regulatory steps.
- The initial ZGN-1061 Phase 2 portion met primary endpoints at 0.9 mg; 12-week data showed favorable safety and tolerability, with no treatment-related serious adverse events or cardiovascular safety signals reported. These early findings do not establish later-stage safety or efficacy.
- Key risks include clinical and regulatory failure, possible thrombotic or other adverse effects given the prior beloranib experience, dependence on third-party manufacturers and clinical organizations, future financing needs, and loan covenants. Zafgen stated it had no material litigation and no material off-balance-sheet arrangements.
- The company had no significant product revenue and expected continued losses. Future R&D spending, trial timing, enrollment, regulatory requirements, and financing availability could differ materially from expectations.
Most important facts for an investor to verify
- Confirm that the intended issuer is Zafgen, Inc., not Larimar Therapeutics, and confirm the filing and reporting period.
- Review the full ZGN-1061 Phase 2 data, including the higher-dose cohort, durability of response, and safety monitoring for thrombotic and cardiovascular events.
- Check whether ZGN-1258’s IND and Phase 1 milestones were achieved and whether timelines or spending changed.
- Verify the post-offering share count, dilution, net proceeds, and updated cash runway against later filings.
- Review term-loan repayment, interest-rate exposure, minimum-liquidity covenants, and any subsequent covenant or financing developments.